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Background: The CCAAT/enhancer-binding protein β (C/EBPβ) is a transcription factor, which was first identified as
a regulator of differentiation and inflammatory processes mainly in adipose tissue and liver; however, its function in
the brain was largely unknown for many years. Previous studies from our laboratory indicated that C/EBPβ is
implicated in inflammatory process and brain injury, since mice lacking this gene were less susceptible to kainic
acid-induced injury.
Methods: We first performed cDNA microarrays analysis using hippocampal RNA isolated from C/EBPβ+/+ and
C/EBPβ−/− mice. Immunocytochemical and immunohistochemical studies were done to evaluate C/EBPβ and C3
levels. Transient transfection experiments were made to analyze transcriptional regulation of C3 by C/EBPβ. To
knockdown C/EBPβ and C3 expression, mouse astrocytes were infected with lentiviral particles expressing an shRNA
specific for C/EBPβ or an siRNA specific for C3.
Results: Among the genes displaying significant changes in expression was complement component 3 (C3), which
showed a dramatic decrease in mRNA content in the hippocampus of C/EBPβ−/− mice. C3 is the central component
of the complement and is implicated in different brain disorders. In this work we have found that C/EBPβ regulates C3
levels in rodents glial in vitro and in the rat Substantia nigra pars compacta (SNpc) in vivo following an inflammatory
insult. Analysis of the mouse C3 promoter showed that it is directly regulated by C/EBPβ through a C/EBPβ consensus
site located at position −616/-599 of the gene. In addition, we show that depletion of C/EBPβ by a specific shRNA
results in a significant decrease in the levels of C3 together with a reduction in the increased levels of pro-inflammatory
agents elicited by lipopolysaccharide treatment.
Conclusions: Altogether, these results indicate that C3 is a downstream target of C/EBPβ, and it could be a mediator of
the pro-inflammatory effects of this transcription factor in neural cells.
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CCAAT/enhancer-binding protein β (C/EBPβ), is a mem-
ber of a family of transcription factors consisting of six
structurally related basic leucine-zipper DNA-binding
proteins. All six members of this family exhibit a high
sequence similarity in their C-terminal DNA binding do-
main and a more diverge regulatory N-terminus [1,2].
C/EBPβ is encoded by a single mRNA, yet translation of
this mRNA results in the synthesis of three C/EBPβ iso-
forms based on alternative translation initiation sites [3,4].
C/EBPβ is expressed in numerous tissues, including liver,
adipose tissue, kidney, lung, ovary, mammary gland, and
hematopoietic tissues and regulates a variety of biological
processes, including metabolism, proliferation and differ-
entiation, and immune response [1,5-7]. This regulation
takes place through the induction or repression of many
genes involved in these processes, such as proliferative- or
differentiation-related markers, cytokines, and many pro-
inflammatory genes [1,8]. Also, due to its relevance in the
indicated cellular processes, C/EBPβ also is involved in the
pathogenesis of different diseases, for example, cancer,
hyperinflammatory processes, and bacterial infections [1].
Regarding the central nervous system (CNS), it has
been shown that the C/EBPβ gene is expressed in different
areas of adult rodents [9] and different studies, including
those from our group, have indicated that C/EBPβ can
have important functions in the brain. It has been shown
that C/EBPβ plays an important role in the consolidation
of long-term memory, suggesting a very important role for
this protein in the hippocampus [10,11] and Menard et al.
have defined a MEK-C/EBP pathway as being essential for
the differentiation of cortical progenitor cells into postmi-
totic neurons [12]. In this regard, we have demonstrated
that C/EBPβ serves as a critical factor in neuronal differ-
entiation [13]. More recently we have demonstrated that
C/EBPβ regulates the expression of several genes involved
in inflammatory processes and brain injury [14] and mice
lacking C/EBPβ showed a reduced inflammatory response
after kainic acid injection and exhibited a dramatic reduc-
tion in pyramidal cell loss in the CA1 and CA3 subfields
of the hippocampus [15]. These data reveal an essential
function for C/EBPβ in the pathways leading to brain
damage and suggest that C/EBPβ should be considered as
a therapeutic target in brain injury and neurodegenerative
disorders where neuronal cell death and inflammation are
involved. Finally, we have also shown that C/EBPβ is
expressed in the dentate gyrus of the hippocampus and
has a key role in regulating the proliferation and differenti-
ation of the stem/progenitor cell population [16].
The complement system plays important roles in the
immune response, including chemotaxis, phagocytosis,
cell adhesion, and B and T cell differentiation [17,18],
and it is a very important line of defense against infec-
tions through the elimination of invading pathogens andregulation of the adaptive immune response [19,20]. More
recent works show that complement components can be
produced by astrocytes, microglia and neurons and that
the complement system also plays important roles in the
CNS that extend far beyond host defense and inflamma-
tory processes [21-27]. Complement component 3 (C3) is
a 185-kDa glycoprotein, which is the central player in the
complement cascade and is involved in opsonization of
pathogens, inflammatory processes, and immune response
[28]. Regarding the brain, C3 has been shown to be essen-
tial for the elimination, or pruning, of incorrect synapsis
during development [26,29,30]. In fact, mice deficient
in C3 exhibit deficits in synaptic remodeling, increased
synaptic connectivity, and enhanced epileptiform activity
due to failed synaptic pruning [31]. Also, it has been
shown that C3 regulates hippocampal neurogenesis in
adult mammalian brain [32] and C3-deficient mice present
impaired neurogenesis following cerebral ischemia [33,34].
These results point to C3 as a positive regulator of both
basal and ischemia-induced neurogenesis.
Besides its role in the CNS in physiological conditions,
uncontrolled complement activation in the brain also has
been shown to be involved in the neuroimmunological and
inflammatory processes that underlie the pathophysiology
of many acute and neurodegenerative disorders, including
Alzheimer’s, Parkinson’s, dementia, meningoencephalitis,
and multiple sclerosis [25,35-42]. Increased levels of C3
have been found in the cerebrospinal fluid (CSF) of patients
with Parkinson’s and Alzheimer’s diseases and these levels
augment with the progression of the disease [42]. Zanjani
et al. showed that C3 localized surrounding β-amyloid
plaques in early stages of Alzheimer disease, when an
important loss of synapsis takes place [43]. Also, en-
hanced synthesis of different complement components
has been reported in animal models of neurodegeneration
and neuroinflammation, such as exposure to neurotoxins,
virus-induced encephalomyelitis, and excitotoxic kainic
acid lesion [44-47].
In this work, we have analyzed the regulation of C3 by
C/EBPβ and its possible involvement as a mediator of
the effects of C/EBPβ in inflammatory processes. First,
we have shown, by microarray and quantitative RT-PCR
analysis, a dramatic decrease in C3 mRNA content in
the hippocampus of C/EBPβ knockout mice. The ana-
lysis of the mouse C3 promoter showed that C3 is dir-
ectly regulated by C/EBPβ, primarily through a C/EBPβ
consensus site located at position −616/-599 of the
gene. Expression studies showed a parallel induction of
C/EBPβ and C3 proteins by lipopolysaccharide (LPS)
in vitro in primary cultures of astrocytes and microglial
cells and in vivo in the Substantia nigra pars compacta
(SNpc) of adult rats. Ectopic expression of C/EBPβ in
mouse cultured astrocytes induced the expression of the
endogenous C3 gene. On the other hand, depletion of
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levels together with a reduction in interleukin-1β (IL-1β)
and cyclooxygenase type 2 (COX-2), after LPS treatment.
Altogether, these results suggest a direct role of C3 in
the pro-inflammatory effects of C/EBPβ.
Methods
Animals
Adult male Wistar rats (8 to 12-weeks old) and neonatal
Wistar rats (2-days-old) were used throughout the study.
Microarrays analysis was performed in adult C/EBPβ+/+ and
C/EBPβ−/− mice. C/EBPβ+/+ and C/EBPβ−/− mice were gen-
erated from heterozygous breeding pairs, kindly provided by
C. M. Croniger and R. W. Hanson (Case Western Reserve
University, Cleveland, OH) [48]. Genotypes were identified
using genomic PCR, with DNA prepared from tail using the
REDExtract-N-AmpTM tissue PCR kit (XNAT kit, Sigma-
Aldrich, Madrid, Spain). All procedures with animals were
specifically approved by the Ethics Committee for Animal
Experimentation of the Instituto de Investigaciones Biome-
dicas and carried out in accordance with the European
Communities Council, directive 86/609/EEC. Special care
was taken to minimize pain or discomfort of animals.
Microarray analysis
Total RNA was extracted from hippocampus of C/EBPβ+/+
and C/EBPβ−/− mice using Trizol (Agilent Technologies,
Madrid, Spain) and the integrity of RNA confirmed in an
Agilent 2100 Bioanalyzer. The microarray analysis (seven
wild type and seven knockouts samples) was performed
using the G4122F Whole Mouse Genome Microarray
Kit (Agilent Technologies, Madrid, Spain), at the CNIC
Genomic Department. The chips were scanned using the
Agilent G2567AA Microarray Scanner System (Agilent
Technologies, Madrid, Spain). Image analysis and data col-
lection were carried out using the Agilent Feature Extrac-
tion 9.1.3.1. (AFE, Agilent Technologies, Madrid, Spain).
The AFE algorithm yields a background-adjusted signal by
subtracting the background signal from the mean signal.
Real-time PCR
Total hippocampal RNA samples (2 μg) were used for
the synthesis of cDNA by reverse transcription using the
Reverse Transcription System (Promega Corporation,
Madrid, Spain) with a pd(N)6 random hexamer. Real-time
PCR was performed in an ABI Prism machine using the
SYBR Green PCR Master Mix (Applied Biosystems,
Madrid, Spain) and 300 nM concentrations of specific pri-
mer. The primers used for the determination of the con-
centration of C3 mRNA were: 5’-ACC TTA CCT CGG
CAA GTT TCT-3’ (forward sequence) and 5’-TTG TAG
AGC TGC TGG TCA GG- 3’ (reverse sequence), which
synthesized a fragment of 140 bp. In all runs, melting
curves were performed to ensure that only one DNAfragment was amplified. Cycle threshold for wild type mice
(dilution 1:10) was around 25. Amplification of the 18S
rRNA was used for normalization of cDNA loading in the
PCR as previously described [49]. The relative mRNA con-
tent was determined with the 2 -Δ ΔCt method [50].
Cells culture, gene silencing and lentiviral infection
GL261 murine glioblastoma cells were obtained from
the NCI-Frederick Cancer Research Tumor Repository
(Frederick, MD) and propagated in RPMI medium with
10% fetal bovine serum as described [51]. Rat and mouse
primary astrocyte and microglial cultures were prepared
as previously described [52]. Cultures were stimulated
with LPS (10 μg/ml) and cells harvested 24 hours later
for evaluation of C/EBPβ and C3 content.
For C3 silencing, mouse astrocytes were grown in
60-mm plates and transiently transfected with 150 pmoles
of an siRNA specific for C3 (Santa Cruz Biotechnology,
Heidelberg, Germany) using Lipofectamine (as indicated by
the manufacturer). The control siRNA also was provided
by Santa Cruz Biotechnology. After 24 hours of transfec-
tion, plates were treated with LPS at a concentration of
10 μg/ml, and 48 hours later plates were washed twice with
cold PBS 1× and processed for protein extraction.
To knockdown C/EBPβ expression, mouse astrocytes
were infected with lentiviral particles expressing a shRNA
specific for C/EBPβ. The interfering sequence was: GAG
CGACGAGTACAAGATG [53]. Annealed oligonucleo-
tides were cloned into pGreenPuroTM shRNA lentiviral
vector (Cloning and Expression Lentivector; SBI, System
Biosciences, Mountain View, CA, USA), according to the
manufacter’s protocol, in which shRNA was expressed
under the control of the H1 promoter. The control
pGreenPuro™ construct with the luciferase shRNA
Template provided by System Biosciences was used as
control in all the experiments. The lentiviral particles
were obtained in HEK293T cells, which were transfected
with the appropriate lentiviral expression vectors and the
third generation packaging vectors pMD2-G, pMDLg/
pRRE, and pRSV-Rev [54]. The medium containing the
lentiviruses was recovered, filtered through a 0.45-μm fil-
ter and used to infect astrocytes. The infection was re-
peated 12 h and 24 h later. After 14 h from the last
infection, half of the plates of each of the groups were
treated with LPS (10 μg/ml) for 24 h after which all plates
were processed for extraction of protein.
Promoter cloning and luciferase assay
A fragment of the mouse C3 promoter, from −1624/+87,
was PCR-amplified from mouse genomic DNA using spe-
cific primers and high-fidelity Eppendorf Triple Master
PCR System (Eppendorf, Hamburg, Germany). The primers
used were: 5’-GGA GAA CAA TAC AGA GAG GAG G-3’
(forward sequence) and 5’-AGT GAA GGA AAA AGG
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fragment, P.C3/1711 was sequenced and subcloned in
the promoterless luciferase reporter vector pGL4.10. Also,
two shorter fragments (−255/+42; P.C3/297) and −79/+42;
P.C3/121) were PCR amplified from the P.C3/1711 frag-
ment. Point mutations were generated by PCR using spe-
cific mutated primers and the Quick Change Site-Directed
Mutagenesis Kit (Agilent Technologies, Madrid, Spain).
This system uses the Pfu Turbo DNA Polymerase and
subsequent digestion with DpnI, to eliminate the methyl-
ated parental band. Mutations were confirmed by sequen-
cing. Mutated primers were: P.C3/MutA: 5’-AAG TAG
GGC CCG GGT CCT GCC CAG CAA CTG A-3 (for the
C/EBPβ binding site located at −616/-599) and P.C3/
MutB: 5’-CTT AGG AAA CGC ACA ATG TCT CAA
GTG GGC AGT CCC-3’ (for the C/EBPβ binding site at
positions −108/-94). For transient transfection expe-
riments, semiconfluent GL261 cells were grown in 24-
well plates and transfected with lipofectamine 2000
(Invitrogen, Madrid, Spain) using the different constructs
described above (1.5 μg DNA/well) in the presence or ab-
sence of the C/EBPβ overexpression plasmid pcDNA3-C/
EBPβ (2 μg DNA/well). Forty-eight hours after transfec-
tion, cells were harvested and the luciferase activity
determined using a reporter assay system (Promega
Corporation, Madrid, Spain). β-galactosidase was used to
determine transfection efficiency.
Chromatin immunoprecipitation
Primary cultures of mouse astrocytes were treated with
LPS (10 μg/ml) and 24 hr later chromatin immunoprecipi-
tation (ChIP) assay was performed, following the manufac-
turer’s recommendations (Santa Cruz Biotechnology). For
immunoprecipitation, the following antibodies were
used: 5 μg of rabbit polyclonal anti-C/EBPβ (Santa
Cruz Biotechnology) and 2 μg of normal rabbit IgG
(Santa Cruz Biotechnology, Mountain View, CA, USA).
The precipitated DNA was analyzed by PCR using the fol-
lowing primers: C/EBPβ, sense: 5’-TGC CCT CAC CCC
TTATCC TCC TC-3’; antisense: 5’-GGC AGG TTC AGG
AAG GTG GAG AC-3’ (which amplified the C3 promoter
from −669 to −525) and GAPDH, sense: 5’-GAG GTC
CAC CAC CCT GTT GCT GTA GC -3’; antisense 5’-
GCT GAA CGG GAA GCT ACA TGG CAT GG -3’
(which amplified a fragment from +208 to +712). Ther-
mal cycling conditions: one cycle at 95°C for 1 min; 38
cicles at 95°C for 30 s, 60°C for 30 s and 72°C for 30 s;
and one cycle at 72°C for 7 min.
Western blot analysis
Proteins were isolated from cell cultures by standard
methods. A total amount of 30 μg of protein was loaded
on a 6% or 12% SDS-PAGE gel. After electrophoresis, pro-
teins were transferred to protran nitrocellulose membranes(Sigma-Aldrich, Madrid, Spain), and blots were probed
with the indicated primary antibodies, as previously
described [14]. The antibodies used were the follow-
ing: rabbit polyclonal anti-C3 (Abcam, Cambridge, UK),
mouse monoclonal anti-C/EBPβ (Abcam, Cambridge, UK),
goat polyclonal anti-COX2 (Santa Cruz Biotechnologies,
Mountain View, CA, USA), rabbit polyclonal anti-IL1β
(Abcam, Cambridge, UK), rabbit polyclonal anti-α-tubulin
(Sigma-Aldrich, Madrid, Spain) and secondary peroxidase
conjugated antibodies (Jackson Immunoresearch, West
Grove, PA, USA). Quantification was performed using
Scion Image software (Scion Corporation, http://scion-
image.software.informer.com/).
Nitrites measurement
Accumulation of nitrites in media was assayed by the
standard Griess reaction. After 24 hours of transfection
with 150 pmoles of an siRNA specific for C3 or a non-
targeting siRNA, plates were treated with LPS at a con-
centration of 10 μg/ml, and 48 hours later supernatants
were collected and mixed with an equal volume of
Griess reagent (Sigma-Aldrich, Madrid, Spain). Samples
were then incubated at room temperature for 15 mi-
nutes and absorbance read using a plate reader at 492/
540 nm.
Immunocytochemistry
Cells were processed for immunocytochemistry at the
end of the treatment period as previously described [55].
Briefly, primary glial cultures grown on glass cover slips
were washed with PBS, fixed for 30 min with 4% para-
formaldehyde at 25°C and permeabilized for 30 min with
0.1% Triton X-100 at 37°C. After 1 h incubation with
the corresponding primary antibody, cells were washed
with PBS and incubated with Alexa-488 or Alexa-647
secondary antibodies for 45 min at 37°C. Then, 6-
diaminidine-2-phenylindole (DAPI) was used to stain
nuclei. Images were acquired using a Nikon eclipse
90i microscope, equipped with a DS-Fi1 digital camera
(Nikon, Amsterdam, Holland). Microscope settings were
adjusted to optimize signal-to-noise ratios. To compare
fluorescence signals from different preparations, settings
were fixed for all samples within the same analysis. The fol-
lowing primary antibodies were used: rabbit polyclonal
anti-C3 (Abcam, Cambridge, UK), mouse monoclonal
anti-C/EBPβ (Abcam, Cambridge, UK).
Lipopolysaccharide injection in vivo
Adult male rats were anesthetized by intraperitoneal
injection of ketamine (60 mg/kg) and medetomidine
(0.125 mg/kg) and positioned in a stereotaxic apparatus
(Kopf Instruments, Tujunga, CA, USA). LPS (10 μg in 2.5 μl
PBS) was injected into the right side of the SNpc (coordi-
nates from Bregma: posterior −4.8 mm; lateral +2.0 mm;
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Watson) with a 10-μl Hamilton syringe. Flow rate (1 μl/min)
was kept constant with a motorized syringe pump (BASi,
West Lafayette, IN, USA) and the needle was kept in
place for 2 min postinjection before being slowly with-
drawn. Control animals of the same age were injected
with vehicle. Rats were then housed individually to
recover and sacrificed 72 h after lesioning with LPS.
Immunohistochemistry
Rats previously anesthetized were perfused transcar-
dially with 4paraformaldehyde, and brains removed,
postfixed and processed for immunohistochemistry as
previously described [56]. The following primary anti-
bodies were used: rabbit polyclonal anti-C3 (Abcam,
Cambridge, UK), mouse monoclonal anti-C/EBPβ (Abcam,
Cambridge, UK), rabbit anti-tyrosine hydroxylase (TH,
Chemicon International Inc., Madrid, Spain) and rabbit
polyclonal anti-glial fibrillary acidic protein (GFAP, Dako,
Glostrup, Denmark). Neurotrace fluorescent Nissl stainTable 1 Genes regulated by C/EBPβ involved in immune/infla
Upregulated genes in C/EBPβ+/+
Accession no. Symbol Name
NM_009778 C3 Complement component 3
NM_013590 Lzp-s Plysozyme structural
NM_016972 S1c7a8 Solute carrier family (cationic amino acid tran
y + system), member 8
NM_009662 Alox 5 Arachidonate 5-lipoxygenase
NM_130452 Bbox1 Butyrobetaine (gamma), 2-oxoglutarate dioxy
1 (gamma-butyrobetaine hydroxylase)
NM_027961.1 Wfdc3 WAP four-disulfide core domain 3
NM_026331 S1c25a37 Solute carrier family 25, member 37
NM_053262 Dhrs8 Dehydrogenase/reductase (SDR family) mem
Downregulated genes in C/EPBβ+/+
Accession no. Symbol Name
NM_009628.2 ADNP Activity-dependent neuroprotective protein
NM_008596.1 Sypl2 Synaptophysin-like 2
NM_008380 Inhba Inhibin beta-A
NM_001002927 Penk1 Preproenkephalin 1
NM_172479 S1c38a5 Solute carrier family 38, member 5
NM_010796 Mg11 Macrophage galactose N-acetyl-galactosamin
specific lectin 1
NM_008198 Cfb Complement factor B
NM_026954 Tusc1 Tum or suppressor candidate 1
NM_145575 Cald1 Caldesmon 1(Molecular Probes, Madrid, Spain) and tomato lectin
(Vector Labs, Peterborough, UK) were used to stain neu-
rons and microglial cells, respectively. After being mounted
with Vectashield (Vector labs, Peterborough, UK), samples
were examined with a spectral LSM710 confocal micro-
scope (Zeiss, Madrid, Spain) equipped with a Nikon DS-
Qi1Mc digital camera. To compare fluorescence signals
from different preparations, confocal microscope settings
were fixed for all samples within the same analysis and
adjusted to produce the optimum signal-to-noise ratio.
Activated glial cells (microglia and astrocytes) expressing
C/EBPβ were counted in the SNpc on coronal sections
doubled immunostained with tomato lectin (microglia)
or GFAP (astrocytes) in five well-defined high magnifi-
cation (×400) fields in five animals/experimental group,
using a computer-assisted image analysis software (Soft
Imaging System Corp, Lakewood, CO, USA). Double
C/EBPβ/tomato-lectin or C/EBPβ/GFAP positive cells
counting were expressed as a percentage over the total
number of tomato-lectin+ or GFAP+ cells, respectively.mmatory response
Biological processes
Complement activation, immune and inflammatory response,
response to stress.
Cell wall macromolecule catabolic processes, defence response
to bacterium.
sporter, Integral component of membrane, amino acid transmembrane
transporter activity, toxin transporter activity.
Defence response, response to stress, immune response,
oxidoreductose and dioxygenase activity.
genase Carnitine biosynthesis, adrenal gland development, metabolism.
Inflammation, bacterial opsonization, immune responses.
Mitochondrial biogenesis, neurotransmitter transporter.
ber 8 Steroid dehydrogenase activity, androgen catabolic process,
lipid metabolic process, oxidation-reduction process.
Biological process
Neuropeptide signalling pathway, neurological disorders,
inflammation.
transporter activity, cellular calcium ion homeostasis.
Cytokine-cytokine receptor interaction, growth factor activity,
cell cycle arrest, cellular response to cholesterol.
Response to stress, neuropeptide signalling pathway, signal
transduction.
Amino acid transport across plasma membrane, oxidative
stress, antioxidant defence.
e Inflammation, macrophage polarization.
Response to stress, complement activation, immune response.
Chronic inflammation, cell cycle regulation.
Immune response.
Figure 1 Regulation by C/EBPβ of the activity of the mouse C3 promoter. (A) RT-PCR analysis of C3 mRNA content in the hippocampus of
C/EBPβ+/+ and C/EBPβ−/− mice. The graphic shows the mean ± SD of three different experiments. **P <0.01. (B, C) Analysis, by transient transfection in
GL261 cells, of the effect of different deletions (B) and point mutations (C) on the activity of C3 promoter. Data represent the mean ± SD of luciferase
activity determined in triplicate in at least three independent experiments. ***P <0.001 versus whole (B) or non-mutated (C) C3 promoter; #P <0.05,
###P <0.001 versus C3 basal promoter activity. (D) Representative image of ChIP analysis of C/EBPβ binding to the endogenous C3 promoter in primary
astrocytes. DNA before immunoprecipitation was used as positive control (Input).
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Figure 2 Induction of C/EBPβ and C3 gene expression in mouse astrocytes and microglial cells treated with lipopolysaccharide (LPS).
Astrocytes and microglial cells were cultured and treated with vehicle or LPS (10 μg/ml) and the content of C/EBPβ and C3 proteins determined
24 h later using specific antibodies, as indicated in Methods. (A) Representative western blot showing the levels of C/EBPβ and C3. Quantification
analysis is shown. Values represent the mean ± SD of five different experiments. *P <0.05, **P <0.01. (B, C) Primary astrocytes (B) or microglial
(C) cells were treated as commented above and the expression of C/EBPβ (red) and C3 (green) was evaluated using immunofluorescence techniques,
as described in Methods. Nuclei were stained with DAPI.
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Figure 3 (See legend on next page.)
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(See figure on previous page.)
Figure 3 Effect of C/EBPβ and C3 on IL-1β and COX-2 gene expression in mouse astrocytes. Astrocytes were transiently transfected with
the indicated vectors or oligonucleotides, treated or not with lipopolysaccharide (LPS), and 24 h later the content of C/EBPβ, C3, IL-1β and COX2
proteins analyzed as indicated in Methods. (A) Representative western blot showing expression of C/EBPβ and C3 in astrocytes overexpressing
C/EBPβ (pcDNA3β). Quantification analysis is shown. Data represent the mean ± SD of five different experiments. *P <0.05, ***P <0.001 versus
basal values. (B) Representative western blot showing expression of C/EBPβ, C3, IL-1β, and COX-2 in astrocytes transfected with a C/EBP shRNA and
treated or not with LPS. Quantification analysis is shown. Values represent the mean ± SD of five different experiments. *P <0.05, **P <0,01, ***P <0.001
versus shRNA Ctrl. (C) Representative Western blot showing expression of C3, IL-1β, and COX-2 in astrocytes transfected with C3 siRNA and treated or
not with LPS. Quantification analysis is shown. Values represent the mean ± SD of five different experiments. (D) Astrocytes were transfected with C3
siRNA or a non-targeting siRNA (siRNA Ctrl), treated or not with LPS and nitrite production was measured as indicated in Methods. ***P <0.001 versus
siRNA Ctrl + LPS.
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Microarray analysis
The comparison of the hippocampal transcriptoma be-
tween wild type and C/EBPβ knockout mice rendered 33
genes differentially expressed. Eighteen of these genes
are genes that have been related with inflammation and
cellular damage (Table 1). Among those genes, we found
C3, which is a factor that plays a central role in the function
of the complement system. The content of C3 transcripts
was markedly reduced in the hippocampus of C/EBPβ−/−
mice compared with control ones, and subsequently in
this work, we pursued the study of the possible role of
this gene in the pro-inflammatory and neural damage
effects of C/EBPβ.
C/EBPβ regulates the activity of the mouse C3 promoter
We initially confirmed, by real time PCR, the decrease
in C3 mRNA content in the hippocampus of C/EBPβ−/−
mice indicated by the microarray analysis. Our results
showed an 80% decrease in the content of C3 transcripts
in the hippocampus of knockout mice compared with
controls (Figure 1A). To further substantiate the role of
C/EBPβ in regulating C3 gene expression, we studied
whether C/EBPβ regulates C3 promoter activity. First,
we performed an in silico analysis to search for putative
C/EBPβ binding sites in the mouse C3 promoter. We
identified two putative consensus binding sites for this
transcription factor located at positions −616/-599
(site A) and −108/-94 (site B). Transient transfection
experiments in GL261 cells showed that the cotransfection
of P.C3/1711 with C/EBPβ significantly (14-fold) induced
the activity of the promoter (Figure 1B), clearly indicating
that C3 promoter responds to C/EBPβ, as suggested by the
in silico analysis. In order to localize the responsive site we
first analyzed the response to C/EBPβ overexpression of
different deletions of C3 promoter. When site A was de-
leted (P.C3/297), the induction by C/EBPβ was drastic-
ally reduced. No effect of C/EBPβ was observed when
both sites, A and B, were deleted (P.C3/121) (Figure 1B).
A more detailed analysis, by point mutation, showed
that site A is essential for the regulation by C/EBPβ of
the mouse C3 promoter. When site A was mutated, theinduction by C/EBPβ of the promoter activity was reduced
from a 14-fold increment in P.C3/1711 to only a 4-fold in-
crease in P.C3/MutA (Figure 1C). In contrast, no effect
was observed when site B was mutated (Figure 1C). All
these results suggest that the C/EBPβ binding site A is the
most important for the regulation by C/EBPβ of the mouse
C3 promoter.
To provide direct evidence that C/EBPβ is recruited
to the endogenous C3 promoter during transcription
in vivo, we performed standard ChIP assays, which allow
the detection of proteins bound to specific regions of DNA
in vivo. For these assays we used primary cultures of astro-
cytes treated with LPS and a specific antibody against
C/EBPβ to precipitate the complex formed by DNA and
this transcription factor. ChIP analysis with C/EBPβ
antibody showed binding of this transcription factor to
the C3 promoter at the C/EBPβ consensus binding site
A (Figure 1D). As a control of specificity of the assay,
binding of C/EBPβ to the housekeeping GAPDH locus
was almost undetectable. These data indicate that C/EBPβ
interacts with the A region of the C3 promoter.Lipopolysaccharide simultaneously induces the expression
of C/EBPβ and C3 genes in primary cultures of mouse
astrocytes and microglial cells
We have previously shown that pro-inflammatory and
cell injury factors induce the expression of C/EBPβ in glial
cells [15]. Here, we used the known pro-inflammatory
factor LPS to induce the expression of C/EBPβ and sim-
ultaneously analyzed the expression of C3 in primary
cultures of mouse astrocytes and microglial cells. Western
blot analysis showed that in astrocytes LPS induced the
expression of both C/EBPβ and C3. As can be seen in
Figure 2A, LPS elicited a significant increase in the content
of C/EBPβ and C3 (six-fold and four-fold, respectively,
compared with non-treated cultures). Immunocytochem-
istry analysis showed similar results with an increase of
C/EBPβ in the nuclei and C3 in the cytosol of astrocytes
(Figure 2B). Interestingly, our results clearly show that
this induction of C/EBPβ and C3 protein levels by LPS oc-
curs in the same cells (Figure 2B). In the case of microglial
Figure 4 (See legend on next page.)
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Figure 4 Induction of C/EBPβ and C3 gene expression in rat astrocytes and microglial cells treated with lipopolysaccharide (LPS).
Astrocytes and microglial cells were cultured and treated with vehicle or LPS (10 μg/ml) and the content of C/EBPβ and C3 proteins determined
24 hours later using specific antibodies, as indicated in Methods. (A) Representative western blot showing the levels of C/EBPβ and C3. Quantification
analysis is shown. Values represent the mean ± SD of five different experiments. *P <0.05, **P <0.01. (B, C) Primary astrocytes (B) or microglial
(C) cells were treated as commented above and the expression of C/EBPβ (red) and C3 (green) was evaluated using immunofluorescence
techniques, as described in Methods. Nuclei were stained with DAPI.
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also was observed (Figure 2C).
Effect of genetic manipulation of C/EBPβ and C3 content
on the expression of IL-1β and COX-2 in mouse astrocytes
So far, our analysis of C3 regulation by C/EBPβ in glial
cells was based in the simultaneous induction of the
expression of both genes by LPS. To further analyze the
regulation of C3 expression by C/EBPβ and to avoid any
C/EBPβ-independent effects of LPS on the expression of
C3, we forced the expression of C/EBPβ by transiently
transfecting mouse astrocytes with the pcDNA3β vector
and analyzed the expression of the endogenous C3 gene.
As shown in Figure 3A the content of C/EBPβ is clearly
increased in transfected cells and simultaneously a two-
fold increase in C3 was observed. In contrast, when the
LPS-induced increase of C/EBPβ was decreased by RNA
interference with an shRNA specific for this transcrip-
tion factor a clear reduction in the induction of C3 gene
expression was observed (Figure 3B). Moreover, IL-1β
and COX2, two well-known inflammatory mediators,
which are induced by C/EBPβ [15] also were decreased
in the presence of C/EBPβ shRNA (Figure 3B). Further-
more, when the LPS induction of C3 was blocked by a
specific siRNA, a clear decrease in IL-1β and COX-2
also was observed (Figure 3C), suggesting that C3 could
play a role in the induction of these inflammatory agents
by C/EBPβ.
Lipopolysaccharide simultaneously induces the
expression of C/EBPβ and C3 genes in primary cultures of
rat astrocytes and microglial cells
Next, we analyzed whether the effect of LPS on the ex-
pression of C/EBPβ and C3 observed in mice cultures of
glial cells also was detected in rat primary cultures of as-
trocytes and microglial cells. As shown in Figure 4, yet
again a parallel increase in cell content of C/EBPβ and
C3 was observed. The western blot results showed an
approximately three- and two-fold increase in C/EBPβ
and C3 content, respectively, in astrocytes (Figure 4A).
Immunocytochemistry analysis also showed a coincident
increase of C/EBPβ in the cell nuclei and C3 in the cyto-
sol of both astrocytes and microglial cells, as previously
observed in mice glial cultures, with a clear colocaliza-
tion of both proteins in the same cells (Figure 4B-C).Effect of lipopolysaccharide injection on the expression of
C/EBPβ and C3 genes in vivo in the SNpc of adult rats
In order to further extend the studies realized in glial
primary cell cultures, we analyzed the effect of LPS in-
jection on C/EBPβ and C3 levels in rats in vivo. For this
purpose, adult rats were injected with either vehicle or
LPS into the SNpc. This brain area, in contrast with
others (such as the hippocampus), is very sensitive to
the action of LPS. Our results show that the injection of
LPS noticeable increased the expression of C/EBPβ and
C3 in the damaged SNpc (Figure 5A) and that the induc-
tion of the expression of these two proteins took place
in the same cells. To identify the cell type specificity of
this activation, we next performed double labeling using
tomato lectin, anti-TH, and anti-GFAP to identify mi-
croglia, dopaminergic cells, and astrocytes, respectively.
C/EBPβ was mostly expressed in microglial cells. Our re-
sults show that microglia accumulated within the dam-
age area, very close to the dopaminergic neurons, and
that they expressed high levels of C/EBPβ. In the case of
astrocytes (GFAP+ cells), we found C/EBPβ expressing
cells in the periphery of the damaged area (Figure 5B).
Quantification analysis (Figure 5C) shows a higher amount
of microglial cells expressing C/EBPβ compared to astro-
cytes. These results differ slightly from those obtained in
in vitro cultures of glial cells where a less number of micro-
glial cells expressed C/EBPβ, compared to the number of
astrocytes expressing this transcription factor.
Discussion
In this work, we have shown that the transcription factor
C/EBPβ directly regulates the expression of the C3 gene,
and that this control could be relevant for the pro-
inflammatory effects of this transcription factor. By
microarray analysis and RT-PCR we showed that the
hippocampal content of C3 transcripts was depleted in
C/EBPβ−/− mice. The analysis of the C3 promoter showed
that this gene was directly induced by C/EBPβ through a
C/EBPβ consensus site located at −616/-599 position from
the transcription start site. In accordance with these data,
LPS induced the expression of C3 in glial cells, at least
in part, through the induction of C/EBPβ since the
repression of LPS-induction of C/EBPβ by shRNA inter-
ference blocked C3 increase. On the contrary, C/EBPβ over-
expression by transient transfection induced C3 expression.
Figure 5 (See legend on next page.)
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Figure 5 Effect of lipopolysaccharide (LPS) on the expression of C/EBPβ and C3 in the SNpc of the rat. Rats were injected with LPS in the
SNpc and 72 hours later the expression of C/EBPβ and C3 was determined as indicated in Methods. (A) Immunohistochemistry analysis of coronal
brain sections showing C/EBPβ and C3 expression in the SNpc of adult rats injected or not with LPS. Labeling was performed using specific
antibodies recognizing C/EBPβ (red) and C3 (green). Nuclei were stained with DAPI (blue). (B) Immunohistochemistry analysis of coronal brain
sections showing C/EBPβ and TH expression in astrocytes and microglia cells in the SNpc of adult rats injected or not with LPS. Labeling was
performed with tomato lectin (to identify microglial cells) and specific antibodies recognizing GFAP (astrocytes, blue), C/EBPβ (green) and TH
(magenta). (C) Quantification of the number of double stained C/EBPβ/tomato-lectin+ and C/EBPβ/GFAP+ cells in the SNpc. Values are expressed
as a percentage of double C/EBPβ/tomato-lectin+ and C/EBPβ/GFAP+ inmmunoreactive cells with respect to the total number of microglial or
astroglial cells, respectively.
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the levels of the pro-inflammatory factors IL-1β and COX-2,
which were significantly reduced in those cells depleted
of C/EBPβ and C3. Finally, we showed that in vivo, LPS
also induced the expression of both C/EBPβ and C3 in
the rat SNpc, an LPS-sensitive area, and that both
proteins colocalized in the same cells. Collectively, our
findings suggest that C3 could be a mediator of the pro-
inflammatory action of C/EBPβ.
Regarding the microarray analysis we found 33 genes,
out of 2,463 genes included in the analysis, for which ex-
pression was altered in the hippocampus of C/EBPβ−/−,
and 18 of these were genes related with inflammatory or
cell injury processes (Table 1). The component 3 of the
complement was the gene that expression was most
markedly decreased in the hippocampus of C/EBPβ−/−
mice (Table 1). Interestingly, in a previous microarray
analysis performed by our group using the neuroblast-
oma cell line TR overexpressing C/EBPβ, we also identi-
fied C3 as a gene regulated by C/EBPβ [14].
The analysis of the mouse C3 promoter showed that
the relevant site for its regulation by C/EBPβ was the
distal C/EBPβ binding site (−616/-599). When this site
was deleted (P.C3/297) or more importantly mutated
(P.C3/MutA), a drastic reduction in the induction by
C/EBPβ of the C3 promoter activity was observed (from a
14-fold induction in P.C3/1711 to a modest 4-fold induc-
tion in P.C3/297 and P.C3/MutA). In contrast, no change
in C/EBPβ activation of the C3 promoter was observed
when the proximal site was mutated. The human C3 pro-
moter has been extensively analyzed regarding its regula-
tion by inflammatory signal, such as interleukin 1 and 6,
and viral infection [57-60]. Consistent with our results,
these studies suggest that the C/EBP proteins play an
important role in the regulation of C3 gene expression.
Specifically, C/EBPβ plays a critical role in the induction
by IL-1β and the repression by the hepatitis C virus of
C3 gene expression [59,60]. However, and in contrast
with our studies, the region of the human C3 promoter in-
volved in C/EBPβ action was located in more proximal
sequences, −131/-93 [59] and −127/-70 [60] from the
transcription start site. Most importantly, in this work we
found, in a physiological setting such as primary astrocytecultures treated with LPS, that the C/EBPβ protein is
enriched in the promoter region expanding from −669
to −525 of the endogenous C3 gene, which is the region
implicated in the regulation by C/EBPβ.
In accordance with the regulation of the C3 promoter
by C/EBPβ we showed that LPS strongly induces the ex-
pression of C/EBPβ and C3 genes in primary cultures of
mouse and rat astrocytes and microglial cells. Both pro-
teins colocalized in the same cells, being C/EBPβ located
in the nucleus and C3 found in the cytoplasm. These re-
sults are in agreement with previous works, including
our reports, showing that in primary cultures of glial
cells, LPS induces the expression of C/EBPβ [15,61]
and also the expression of C3 [62,63]. However, these
authors did not study the regulation of both genes to-
gether nor did they study colocalization in the same
cells. Also, the results presented here are consistent with
a previous report [64] showing a parallel induction by
LPS of C/EBPβ and C3 mRNAs in mouse astrocytes,
suggesting that C/EBPβ could play an important role in
LPS induction of C3 gene expression. The notion that
C3 is regulated by C/EBPβ under inflammatory condi-
tions is further supported by our data showing that the
increase in both proteins, as commented above, occurs
in the same cells and that the induction of C3 by LPS
was abolished when the expression of C/EBPβ is blocked
by a specific shRNA. Moreover, the overexpression of
C/EBPβ, by transient transfection, induces the expres-
sion of the C3 gene in mouse astrocytes in the absence
of LPS.
C/EBPβ plays an important role in mediating the effect
of diverse pro-inflammatory stimuli, including LPS [65],
as a consequence of its induction of pro-inflammatory
genes such as IL-1β and COX-2, among others. In agree-
ment with this we showed here that when the LPS-
induced increase in C/EBPβ was inhibited in astrocytes
by a C/EBPβ specific shRNA, a marked decrease in
IL-1β and COX-2 induction was observed. In line with
these data, we have previously shown a marked decrease
in the induction of IL-1β and COX-2 elicited by LPS in
microglial cells from C/EBPβ−/− mice [15]. In addition,
when the induction of C3 by LPS was specifically inhib-
ited by a specific C3 siRNA, a parallel reduction was
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COX-2 levels, suggesting that C3 could play an import-
ant role as a mediator of the proinflammatory effects of
C/EBPβ in neural cells. Consistent with this notion, a
neuroinflammatory role of C3 in different models of brain
injury has been shown [66,67]. In addition to the well-
described pro-inflammatory effects of C/EBPβ, this tran-
scription factor also regulates many relevant cellular
functions, including proliferation, differentiation, metabol-
ism, and immune response [68]. In this regard, it is inter-
esting to point out that treatment of human microglial
cultures with macrophage-colony stimulating factor en-
hances proliferation and a change in the morphology of
these cells (towards a less activated phenotype, which
is accompanied by a parallel increase in C/EBPβ levels
[69]). These results are somehow in contrast with the data
presented here clearly showing a pro-inflammatory effect
of this transcription factor. Since it is widely accepted the
pro-inflammatory effects of C/EBPβ, and specifically its ef-
fects on microglial cells [14,15,70,71], this apparent dis-
crepancy may be due to the different properties of human
versus rodent microglia [72].
Finally, we have demonstrated for the first time an in-
duction of C3 and C/EBPβ protein levels in vivo after
treatment with LPS. Our results show that the in vivo
injection of LPS into the SNpc of adult rats, a brain
area known to be sensitive to the neurodegenerative
effects of LPS, results in a strong induction of both
C/EBPβ and C3 in the glial cells found in the SNpc and
in adjacent areas. Importantly, both proteins colocalized
in the same cells, further supporting the notion that
C/EBPβ regulates C3 expression during inflammatory
processes.
Conclusions
In summary, our results clearly show that C3 gene ex-
pression is under the direct regulation of the transcription
factor C/EBPβ in activated glial cells and suggest that C3
could play an important role in the pro-inflammatory ef-
fect of this transcription factor in the brain.
Abbreviations
C/EBPβ: CCAAT/enhancer-binding protein β; ChIP: Chromatin
immunoprecipitation; CNS: Central nervous system; COX-2: Cyclooxygenase
type 2; CSF: cerebrospinal fluid; C3: Complement component 3;
DAPI: 6-diaminidine-2-phenylindole; GFAP: Glial fibrillary acidic protein;
IL-1β: Interleukin-1β; LPS: Lipopolysaccharide; SNpc: Substantia nigra pars
compacta; TH: Tyrosine hydroxylase.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
APC and AS conceived and designed the experiments. EHE, DAM, MCC,
JAMG, and EG performed the experiments. DAM, EHE, APC, and AS analyzed
the data. APC and AS wrote the manuscript. All authors read and approved
the final manuscript.Acknowledgements
This work was supported by the Ministry of Science and Innovation Grant
SAF2010-16365. JAMG was supported by CIBERNED.
Author details
1Instituto de Investigaciones Biomédicas, (CSIC-UAM), Arturo Duperier, 4,
28029 Madrid, Spain. 2Centro de Investigación Biomédica en Red sobre
Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.
3Present address: Laboratory of Neurobiology and Genetics, The Rockefeller
University, 1230 York Avenue, New York, NY 10065, USA. 4Departamento de
Bioquímica y Biologia Molecular, Facultad de Medicina, UCM, Plaza Ramón y
Cajal s/n, 28040 Madrid, Spain.
Received: 12 September 2014 Accepted: 16 December 2014References
1. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and
regulation. Biochem J. 2002;365:561–75.
2. Tsukada J, Yoshida Y, Kominato Y, Auron PE. The CCAAT/enhancer (C/EBP)
family of basic-leucine zipper (bZIP) transcription factors is a multifaceted
highly-regulated system for gene regulation. Cytokine. 2011;54:6–19.
3. Calkhoven CF, Muller C, Leutz A. Translational control of C/EBPalpha and
C/EBPbeta isoform expression. Genes Dev. 2000;14:1920–32.
4. Wethmar K, Smink JJ, Leutz A. Upstream open reading frames: molecular
switches in (patho)physiology. Bioessays. 2010;32:885–93.
5. Poli V. The role of C/EBP isoforms in the control of inflammatory and native
immunity functions. J Biol Chem. 1998;273:29279–82.
6. Croniger C, Leahy P, Reshef L, Hanson RW. C/EBP and the control of
phosphoenolpyruvate carboxykinase gene transcription in the liver. J Biol
Chem. 1998;273:31629–32.
7. Lekstrom-Himes J, Xanthopoulos KG. Biological role of the CCAAT/
enhancer-binding protein family of transcription factors. J Biol Chem.
1998;273:28545–8.
8. Csoka B, Nemeth ZH, Virag L, Gergely P, Leibovich SJ, Pacher P, et al. A2A
adenosine receptors and C/EBPbeta are crucially required for IL-10 production
by macrophages exposed to Escherichia coli. Blood. 2007;110:2685–95.
9. Sterneck E, Johnson PF. CCAAT/enhancer binding protein beta is a neuronal
transcriptional regulator activated by nerve growth factor receptor
signaling. J Neurochem. 1998;70:2424–33.
10. Alberini CM, Ghirardi M, Metz R, Kandel ER. C/EBP is an immediate-early
gene required for the consolidation of long-term facilitation in Aplysia. Cell.
1994;76:1099–114.
11. Taubenfeld SM, Milekic MH, Monti B, Alberini CM. The consolidation of new
but not reactivated memory requires hippocampal C/EBPbeta. Nat Neurosci.
2001;4:813–8.
12. Menard C, Hein P, Paquin A, Savelson A, Yang XM, Lederfein D, et al.
An essential role for a MEK-C/EBP pathway during growth factor-regulated
cortical neurogenesis. Neuron. 2002;36:597–610.
13. Cortes-Canteli M, Pignatelli M, Santos A, Perez-Castillo A. CCAAT/enhancer-
binding protein beta plays a regulatory role in differentiation and apoptosis
of neuroblastoma cells. J Biol Chem. 2002;277:5460–7.
14. Cortes-Canteli M, Wagner M, Ansorge W, Perez-Castillo A. Microarray analysis
supports a role for ccaat/enhancer-binding protein-beta in brain injury.
J Biol Chem. 2004;279:14409–17.
15. Cortes-Canteli M, Luna-Medina R, Sanz-Sancristobal M, Alvarez-Barrientos A,
Santos A, Perez-Castillo A. CCAAT/enhancer binding protein beta deficiency
provides cerebral protection following excitotoxic injury. J Cell Sci.
2008;121:1224–34.
16. Cortes-Canteli M, Aguilar-Morante D, Sanz-Sancristobal M, Megias D, Santos A,
Perez-Castillo A. Role of C/EBPbeta transcription factor in adult hippocampal
neurogenesis. PLoS One. 2011;6:e24842.
17. Frank MM, Fries LF. The role of complement in inflammation and
phagocytosis. Immunol Today. 1991;12:322–6.
18. Gasque P. Complement: a unique innate immune sensor for danger signals.
Mol Immunol. 2004;41:1089–98.
19. Flierl MA, Rittirsch D, Huber-Lang MS, Stahel PF. Complement in human
disease. Clin Dev Immunol. 2013;2013:920474.
20. Song WC, Sarrias MR, Lambris JD. Complement and innate immunity.
Immunopharmacology. 2000;49:187–98.
Hernandez-Encinas et al. Journal of Neuroinflammation  (2015) 12:14 Page 15 of 1621. Benoit ME, Tenner AJ. Complement protein C1q-mediated neuroprotection
is correlated with regulation of neuronal gene and microRNA expression.
J Neurosci. 2011;31:3459–69.
22. Fourgeaud L, Boulanger LM. Synapse remodeling, compliments of the
complement system. Cell. 2007;131:1034–6.
23. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system
for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–97.
24. Rutkowski MJ, Sughrue ME, Kane AJ, Ahn BJ, Fang S, Parsa AT. The
complement cascade as a mediator of tissue growth and regeneration.
Inflamm Res. 2010;59:897–905.
25. Stephan AH, Barres BA, Stevens B. The complement system: an unexpected
role in synaptic pruning during development and disease. Annu Rev
Neurosci. 2012;35:369–89.
26. Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N,
et al. The classical complement cascade mediates CNS synapse elimination.
Cell. 2007;131:1164–78.
27. Veerhuis R, Nielsen HM, Tenner AJ. Complement in the brain. Mol Immunol.
2011;48:1592–603.
28. Sahu A, Lambris JD. Structure and biology of complement protein C3, a
connecting link between innate and acquired immunity. Immunol Rev.
2001;180:35–48.
29. Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R,
et al. Microglia sculpt postnatal neural circuits in an activity and
complement-dependent manner. Neuron. 2012;74:691–705.
30. Zipfel GJ, Babcock DJ, Lee JM, Choi DW. Neuronal apoptosis after CNS
injury: the roles of glutamate and calcium. J Neurotrauma. 2000;17:857–69.
31. Libbey JE, Kirkman NJ, Wilcox KS, White HS, Fujinami RS. Role for
complement in the development of seizures following acute viral infection.
J Virol. 2010;84:6452–60.
32. Moriyama M, Fukuhara T, Britschgi M, He Y, Narasimhan R, Villeda S, et al.
Complement receptor 2 is expressed in neural progenitor cells and
regulates adult hippocampal neurogenesis. J Neurosci. 2011;31:3981–9.
33. Rahpeymai Y, Hietala MA, Wilhelmsson U, Fotheringham A, Davies I,
Nilsson AK, et al. Complement: a novel factor in basal and ischemia-
induced neurogenesis. EMBO J. 2006;25:1364–74.
34. Shinjyo N, Stahlberg A, Dragunow M, Pekny M, Pekna M. Complement-
derived anaphylatoxin C3a regulates in vitro differentiation and migration of
neural progenitor cells. Stem Cells. 2009;27:2824–32.
35. Gasque P, Singhrao SK, Neal JW, Wang P, Sayah S, Fontaine M, et al.
The receptor for complement anaphylatoxin C3a is expressed by
myeloid cells and nonmyeloid cells in inflamed human central nervous
system: analysis in multiple sclerosis and bacterial meningitis. J Immunol.
1998;160:3543–54.
36. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson’s
disease. Parkinsonism Relat Disord. 2004;10 Suppl 1:S3–7.
37. Aiyaz M, Lupton MK, Proitsi P, Powell JF, Lovestone S. Complement
activation as a biomarker for Alzheimer’s disease. Immunobiology.
2012;217:204–15.
38. Cervera A, Planas AM, Justicia C, Urra X, Jensenius JC, Torres F, et al.
Genetically-defined deficiency of mannose-binding lectin is associated with
protection after experimental stroke in mice and outcome in human stroke.
PLoS One. 2010;5:e8433.
39. Lopez ME, Klein AD, Scott MP. Complement is dispensable for
neurodegeneration in Niemann-Pick disease type C. J Neuroinflammation.
2012;9:216.
40. Prineas JW, Parratt JD. Oligodendrocytes and the early multiple sclerosis
lesion. Ann Neurol. 2012;72:18–31.
41. Proitsi P, Lupton MK, Dudbridge F, Tsolaki M, Hamilton G, Daniilidou M,
et al. Alzheimer’s disease and age-related macular degeneration have
different genetic models for complement gene variation. Neurobiol Aging.
2012;33(8):1843. e9-17.
42. Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, et al.
Complement 3 and factor h in human cerebrospinal fluid in Parkinson’s
disease, Alzheimer’s disease, and multiple-system atrophy. Am J Pathol.
2011;178:1509–16.
43. Zanjani H, Finch CE, Kemper C, Atkinson J, McKeel D, Morris JC, et al.
Complement activation in very early Alzheimer disease. Alzheimer Dis Assoc
Disord. 2005;19:55–66.
44. Akiyama H, Tooyama I, Kondo H, Ikeda K, Kimura H, McGeer EG, et al. Early
response of brain resident microglia to kainic acid-induced hippocampal
lesions. Brain Res. 1994;635:257–68.45. Dietzschold B, Schwaeble W, Schafer MK, Hooper DC, Zehng YM, Petry F,
et al. Expression of C1q, a subcomponent of the rat complement system, is
dramatically enhanced in brains of rats with either Borna disease or
experimental allergic encephalomyelitis. J Neurol Sci. 1995;130:11–6.
46. Goldsmith SK, Wals P, Rozovsky I, Morgan TE, Finch CE. Kainic acid and
decorticating lesions stimulate the synthesis of C1q protein in adult rat
brain. J Neurochem. 1997;68:2046–52.
47. Rozovsky I, Morgan TE, Willoughby DA, Dugichi-Djordjevich MM, Pasinetti GM,
Johnson SA, et al. Selective expression of clusterin (SGP-2) and complement
C1qB and C4 during responses to neurotoxins in vivo and in vitro. Neuroscience.
1994;62:741–58.
48. Screpanti I, Romani L, Musiani P, Modesti A, Fattori E, Lazzaro D, et al.
Lymphoproliferative disorder and imbalanced T-helper response in C/EBP
beta-deficient mice. Embo J. 1995;14:1932–41.
49. Asua T, Bilbao A, Gorriti MA, Lopez-Moreno JA, Del Mar AM, Navarro M,
et al. Implication of the endocannabinoid system in the locomotor
hyperactivity associated with congenital hypothyroidism. Endocrinology.
2008;149:2657–66.
50. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods.
2001;25:402–8.
51. El Andaloussi A, Sonabend AM, Han Y, Lesniak MS. Stimulation of TLR9 with
CpG ODN enhances apoptosis of glioma and prolongs the survival of mice
with experimental brain tumors. Glia. 2006;54:526–35.
52. Morales-Garcia JA, Palomo V, Redondo M, Alonso-Gil S, Gil C, Martinez A,
et al. Crosstalk between phosphodiesterase 7 and glycogen synthase
kinase-3: two relevant therapeutic targets for neurological disorders. ACS
Chem Neurosci. 2014;5:194–204.
53. Aguilar-Morante D, Cortes-Canteli M, Sanz-Sancristobal M, Santos A, Perez-
Castillo A. Decreased CCAAT/enhancer binding protein beta expression
inhibits the growth of glioblastoma cells. Neurosci. 2011;176:110–9.
54. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, et al. A third-
generation lentivirus vector with a conditional packaging system. J Virol.
1998;72:8463–71.
55. Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martinez A, Perez-
Castillo A. Regulation of inflammatory response in neural cells in vitro by
thiadiazolidinones derivatives through peroxisome proliferator-activated
receptor {gamma} activation. J Biol Chem. 2005;280:21453–62.
56. Morales-Garcia JA, Redondo M, Alonso-Gil S, Gil C, Perez C, Martinez A, et al.
Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular
and rodent models of Parkinson disease. PLoS One. 2011;6:e17240.
57. Bruder C, Hagleitner M, Darlington G, Mohsenipour I, Wurzner R, Hollmuller I,
et al. HIV-1 induces complement factor C3 synthesis in astrocytes and neurons
by modulation of promoter activity. Mol Immunol. 2004;40:949–61.
58. Juan TS, Wilson DR, Wilde MD, Darlington GJ. Participation of the
transcription factor C/EBP delta in the acute-phase regulation of the
human gene for complement component C3. Proc Natl Acad Sci U S A.
1993;90:2584–8.
59. Maranto J, Rappaport J, Datta PK. Regulation of complement component
C3 in astrocytes by IL-1beta and morphine. J Neuroimmune Pharmacol.
2008;3:43–51.
60. Mazumdar B, Kim H, Meyer K, Bose SK, Di Bisceglie AM, Ray RB, et al.
Hepatitis C virus proteins inhibit C3 complement production. J Virol.
2012;86:2221–8.
61. Ejarque-Ortiz A, Medina MG, Tusell JM, Perez-Gonzalez AP, Serratosa J,
Saura J. Upregulation of CCAAT/enhancer binding protein beta in activated
astrocytes and microglia. Glia. 2007;55:178–88.
62. Haga S, Aizawa T, Ishii T, Ikeda K. Complement gene expression in mouse
microglia and astrocytes in culture: comparisons with mouse peritoneal
macrophages. Neurosci Lett. 1996;216:191–4.
63. Rus HG, Kim LM, Niculescu FI, Shin ML. Induction of C3 expression in
astrocytes is regulated by cytokines and Newcastle disease virus. J Immunol.
1992;148:928–33.
64. Cardinaux JR, Allaman I, Magistretti PJ. Pro-inflammatory cytokines induce
the transcription factors C/EBPbeta and C/EBPdelta in astrocytes. Glia.
2000;29:91–7.
65. Roos AB, Nord M. The emerging role of C/EBPs in glucocorticoid signaling:
lessons from the lung. J Endocrinol. 2012;212:291–305.
66. Ingersoll SA, Martin CB, Barnum SR, Martin BK. CNS-specific expression of
C3a and C5a exacerbate demyelination severity in the cuprizone model.
Mol Immunol. 2010;48:219–30.
Hernandez-Encinas et al. Journal of Neuroinflammation  (2015) 12:14 Page 16 of 1667. Vegeto E, Belcredito S, Etteri S, Ghisletti S, Brusadelli A, Meda C, et al.
Estrogen receptor-alpha mediates the brain antiinflammatory activity of
estradiol. Proc Natl Acad Sci U S A. 2003;100:9614–9.
68. Huber R, Pietsch D, Panterodt T, Brand K. Regulation of C/EBPbeta and
resulting functions in cells of the monocytic lineage. Cell Signal.
2012;24:1287–96.
69. Smith AM, Gibbons HM, Oldfield RL, Bergin PM, Mee EW, Curtis MA,
et al. M-CSF increases proliferation and phagocytosis while modulating
receptor and transcription factor expression in adult human microglia.
J Neuroinflammation. 2013;10:85.
70. Cox GM, Kithcart AP, Pitt D, Guan Z, Alexander J, Williams JL, et al.
Macrophage migration inhibitory factor potentiates autoimmune-mediated
neuroinflammation. J Immunol. 2013;191:1043–54.
71. Straccia M, Gresa-Arribas N, Dentesano G, Ejarque-Ortiz A, Tusell JM,
Serratosa J, et al. Pro-inflammatory gene expression and neurotoxic
effects of activated microglia are attenuated by absence of CCAAT/enhancer
binding protein beta. J Neuroinflammation. 2011;8:156.
72. Dragunow M. The adult human brain in preclinical drug development. Nat
Rev Drug Discov. 2008;7:659–66.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
